Literature DB >> 25323726

Whole-Genome Sequence of Mycobacterium kyorinense.

Kouki Ohtsuka1, Hiroaki Ohnishi2, Eriko Nozaki1, Jesus Pais Ramos3, Enrico Tortoli4, Shota Yonetani1, Satsuki Matsushima1, Yoshitaka Tateishi5, Sohkichi Matsumoto5, Takashi Watanabe1.   

Abstract

We report here the first draft genome sequence of Mycobacterium kyorinense, which was described in 2009 and exhibits significant pathogenicity to humans.
Copyright © 2014 Ohtsuka et al.

Entities:  

Year:  2014        PMID: 25323726      PMCID: PMC4200164          DOI: 10.1128/genomeA.01062-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Mycobacterium kyorinense is a slow-growing mycobacterium that was first described in 2009 (1). M. kyorinense is closely related to M. celatum, M. branderi, and M. fragae, and exhibits significant pathogenicity for humans, causing pneumonia, lymphadenitis, and arthritis (2–4). Antimicrobial susceptibility tests demonstrated that M. kyorinense is generally resistant to rifampin, isoniazid, and ethambutol (4). Further investigation is needed to clarify the genomics, biology, epidemiology, and pathogenicity of this species. We sequenced the genomic DNA of the M. kyorinense type strain KUM060204T on an Ion PGM system (Life Technologies) and assembled the reads using CLC Genomics Workbench 7.0. A total of 4,133,490 reads were generated, with an average read length of 203 bp, yielding a total sequence of 837,657,777 bp. The assembled sequences of KUM060204T comprised 453 contigs, with a combined length of 5,302,980 bp, with a G+C ratio of 66.9%. The average cover depth was 50×, the N50 contig size was 53,523, the average contig was 11,706 bp long, and the longest contig was 137,319 bp. Genome annotation was performed using the RAST prokaryotic genome annotation server (http://www.nmpdr.org/FIG/wiki/view.cgi/Main/RAST). RAST predicted 5,405 putative open reading frames, including 5,351 coding sequences and 54 RNAs (46 tRNAs and 8 rRNAs). RAST functional analysis of the predicted protein-coding genes showed 78 genes involved in cell walls and capsules, 64 in membrane transport, 206 in protein metabolism, 93 in DNA metabolism, 141 in virulence and defense, 135 in respiration, 331 in fatty acids, lipids, and isoprenoids, 395 in cofactors, vitamins, prosthetic groups, and pigments, and 356 in amino acids and derivatives. To explore the molecular mechanism underlying the resistance of M. kyorinense to anti-tuberculosis drugs, we selected several genes known to be responsible for resistance to rifampin (rpoB), ethambutol (embB), and isoniazid (inhA, katG, and ahpC). The sequences of these genes in M. kyorinense were compared with those in M. tuberculosis H37Rv to clarify whether they contain specific mutations associated with resistance to anti-tuberculosis drugs in M. tuberculosis. Analysis of the rpoB gene confirmed our previous finding that KUM060204T harbors a Ser531Asp amino acid substitution, the most frequent mutation in rifampin-resistant M. tuberculosis (4, 5). In contrast, we did not detect a substitution at Met306 of embB, the major mutation in ethambutol-resistant M. tuberculosis (6). Nor did we find a Ser315Thr substitution of katG, a mutation in the regulatory region (nucleotides [nt] −48, −51, −54, −81, and −88) of ahpC, a Ser94Ala substitution in the inhA gene or a mutation in the regulatory region (nt −15 and −17) of inhA, which are common mutations in isoniazid-resistant M. tuberculosis (6). These results suggested that the mechanism underlying drug resistance in M. kyorinense is significantly different from that in M. tuberculosis. In conclusion, we report the genome sequence of KUM060204T which to the best of our knowledge is the first genome sequence of the species M. kyorinense.

Nucleotide sequence accession numbers.

The whole genome sequence of KUM060204T has been deposited in DDBJ/EMBL/GenBank under the accession numbers BBKA01000001 to BBKA01000453.
  5 in total

1.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

2.  First isolation of Mycobacterium kyorinense from clinical specimens in Brazil.

Authors:  Carlos Eduardo Dias Campos; Paulo Cesar de Souza Caldas; Hiroaki Ohnishi; Takashi Watanabe; Kouki Ohtsuka; Satsuki Matsushima; Nicole Victor Ferreira; Mariza Villas Boas da Silva; Paulo Redner; Luciana Distásio de Carvalho; Reginalda Ferreira de Melo Medeiros; Jacyr Antônio Abbud Filho; Fátima Cristina Onofre Fandinho Montes; Teca Calcagno Galvão; Jesus Pais Ramos
Journal:  J Clin Microbiol       Date:  2012-04-18       Impact factor: 5.948

3.  Mycobacterium kyorinense sp. nov., a novel, slow-growing species, related to Mycobacterium celatum, isolated from human clinical specimens.

Authors:  Mitsuhiro Okazaki; Kiyofumi Ohkusu; Hiroyuki Hata; Hiroaki Ohnishi; Keiko Sugahara; Chizuko Kawamura; Nagatoshi Fujiwara; Sohkichi Matsumoto; Yukiko Nishiuchi; Kouichi Toyoda; Hajime Saito; Shota Yonetani; Yoko Fukugawa; Masayuki Yamamoto; Hiroo Wada; Akiko Sejimo; Akio Ebina; Hajime Goto; Takayuki Ezaki; Takashi Watanabe
Journal:  Int J Syst Evol Microbiol       Date:  2009-06       Impact factor: 2.747

4.  Mycobacterium fragae sp. nov., a non-chromogenic species isolated from human respiratory specimens.

Authors:  Jesus Pais Ramos; Carlos Eduardo Dias Campos; Paulo Cesar de Souza Caldas; Nicole Victor Ferreira; Mariza Villas Boas da Silva; Paulo Redner; Creusa Lima Campelo; Sheila Ferreira Vale; Elizabeth Clara Barroso; Reginalda Ferreira de Melo Medeiros; Fátima Cristina Onofre Fandinho Montes; Teca Calcagno Galvão; Enrico Tortoli
Journal:  Int J Syst Evol Microbiol       Date:  2012-12-21       Impact factor: 2.747

5.  Mycobacterium kyorinense infection.

Authors:  Hiroaki Ohnishi; Shota Yonetani; Satsuki Matsushima; Hiroo Wada; Kei Takeshita; Daisuke Kuramochi; Paulo Cesar de Souza Caldas; Carlos Eduardo Dias Campos; Bianca Porphirio da Costa; Jesus Pais Ramos; Shinichirou Mikura; Eriko Narisawa; Akira Fujita; Yasunori Funayama; Yoshihiro Kobashi; Yumi Sakakibara; Yukako Ishiyama; Shunji Takakura; Hajime Goto; Takashi Watanabe
Journal:  Emerg Infect Dis       Date:  2013-03       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.